Cizzle Biotechnology Financials
| CIZ Stock | 1.90 0.20 11.76% |
Return On Equity (1.58) |
Cizzle | Select Account or Indicator |
Understanding current and past Cizzle Biotechnology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cizzle Biotechnology's financial statements are interrelated, with each one affecting the others. For example, an increase in Cizzle Biotechnology's assets may result in an increase in income on the income statement.
Please note, the presentation of Cizzle Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cizzle Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cizzle Biotechnology's management manipulating its earnings.
Cizzle Biotechnology Stock Summary
Cizzle Biotechnology competes with Samsung Electronics, Samsung Electronics, Hyundai, Toyota, and Reliance Industries. Cizzle Biotechnology is entity of United Kingdom. It is traded as Stock on LSE exchange.| Foreign Associate | USA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | UK Stock View All |
| Exchange | London Exchange |
| ISIN | GB00BNG2VN02 |
| Business Address | 60 Gracechurch Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.cizzlebiotechnology.com |
| Phone | 44 20 3934 6630 |
You should never invest in Cizzle Biotechnology without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Cizzle Stock, because this is throwing your money away. Analyzing the key information contained in Cizzle Biotechnology's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Cizzle Biotechnology Key Financial Ratios
There are many critical financial ratios that Cizzle Biotechnology's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Cizzle Biotechnology reports annually and quarterly.| Gross Profit | 25 K | ||||
| EBITDA | (695) | ||||
| Net Income | (1.76 M) | ||||
| Total Asset | 1.69 M | ||||
| Retained Earnings | (7.87 M) |
Cizzle Biotechnology Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 16.5K | 90K | 1.2M | 2.8M | 1.7M | 2.7M | |
| Other Current Liab | 8.9K | 36K | 64K | 96K | 87K | 82.7K | |
| Net Debt | (12.8K) | (84.0K) | (875K) | (478K) | (144K) | (151.2K) | |
| Retained Earnings | (1.6M) | (22.4M) | (5.5M) | (6.2M) | (7.9M) | (8.3M) | |
| Accounts Payable | 946.0 | 22K | 111K | 41K | 92K | 87.4K | |
| Cash | 12.8K | 84K | 875K | 478K | 144K | 136.8K | |
| Inventory | (27.3K) | (3.0) | (80.0) | (227.0) | (1.5M) | (1.5M) | |
| Other Current Assets | 3.7K | 3.0 | 80K | 227K | 136K | 270.9K | |
| Total Liab | 9.8K | 58K | 218K | 145K | 186K | 176.7K | |
| Total Current Assets | 16.5K | 90K | 955K | 705K | 1.7M | 1.5M | |
| Common Stock | 3.1K | 1.2M | 1.3M | 35K | 3.5M | 2.7M | |
| Net Receivables | 31K | 6K | 80K | 227K | 136K | 129.2K | |
| Net Tangible Assets | 6.6K | (8K) | 737K | 560K | 644K | 676.2K | |
| Net Invested Capital | 6.6K | 32K | 937K | 2.6M | 1.5M | 1000.0K | |
| Net Working Capital | 6.6K | 32K | 737K | 560K | 1.5M | 1.6M | |
| Capital Stock | 3.1K | 1.2M | 1.3M | 35K | 37K | 35.2K |
Cizzle Biotechnology Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Operating Income | (21.7K) | (306K) | 2.3M | (963K) | (1.2K) | (1.2K) | |
| Ebit | (21.7K) | (306.0K) | 2.3M | (963K) | (1.7K) | (1.8K) | |
| Ebitda | (21.7K) | (306K) | (851K) | (963K) | (695.0) | (729.75) | |
| Income Before Tax | (21.7K) | (306K) | (4.0M) | (963K) | (1.8K) | (1.9K) | |
| Net Income | (21.7K) | (310K) | (3.9M) | (912K) | (1.7K) | (1.8K) | |
| Income Tax Expense | (2.0) | (77K) | (37K) | (51K) | (46K) | (48.3K) |
Cizzle Biotechnology Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Cizzle Biotechnology. It measures of how well Cizzle is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Cizzle Biotechnology brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Cizzle had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Cizzle Biotechnology has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (7.1K) | (294K) | 868K | (397K) | (334K) | (317.3K) | |
| Free Cash Flow | (7.1K) | (294K) | (1.2M) | (872K) | (639K) | (671.0K) | |
| Other Non Cash Items | (2K) | (12K) | 2.8M | 81K | 828K | 869.4K | |
| Net Income | (21.7K) | (306K) | (4.0M) | (963K) | (1.8M) | (1.9M) | |
| End Period Cash Flow | 12.8K | 84K | 875K | 478K | 144K | 136.8K |
Cizzle Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cizzle Biotechnology's current stock value. Our valuation model uses many indicators to compare Cizzle Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cizzle Biotechnology competition to find correlations between indicators driving Cizzle Biotechnology's intrinsic value. More Info.Cizzle Biotechnology Holdings is rated second in return on equity category among its peers. It is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cizzle Biotechnology's earnings, one of the primary drivers of an investment's value.Cizzle Biotechnology Systematic Risk
Cizzle Biotechnology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cizzle Biotechnology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Cizzle Biotechnology correlated with the market. If Beta is less than 0 Cizzle Biotechnology generally moves in the opposite direction as compared to the market. If Cizzle Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cizzle Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cizzle Biotechnology is generally in the same direction as the market. If Beta > 1 Cizzle Biotechnology moves generally in the same direction as, but more than the movement of the benchmark.
Cizzle Biotechnology Holdings Total Assets Over Time
Cizzle Biotechnology Thematic Clasifications
Cizzle Biotechnology Holdings is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
| Biotech | View |
Cizzle Biotechnology November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cizzle Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cizzle Biotechnology Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cizzle Biotechnology Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Cizzle Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cizzle Biotechnology's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.69 | |||
| Information Ratio | 0.0447 | |||
| Maximum Drawdown | 25.85 | |||
| Value At Risk | (4.76) | |||
| Potential Upside | 7.5 |
Complementary Tools for Cizzle Stock analysis
When running Cizzle Biotechnology's price analysis, check to measure Cizzle Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cizzle Biotechnology is operating at the current time. Most of Cizzle Biotechnology's value examination focuses on studying past and present price action to predict the probability of Cizzle Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cizzle Biotechnology's price. Additionally, you may evaluate how the addition of Cizzle Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |